This is the subject of an evidence base article published today titled “Reflecting on 2025, looking to 2026: Experts outline what to expect for drug pricing and market access”. In the article, various experts consider how 2025 will reshape the global drug pricing and market access landscape as well as predict what to see in 2026. Key topics include the pricing impact of US Inflation Reduction Act (IRA) implementation and renewed most-favoured-nation (MFN) momentum, the growing importance of direct-to-consumer channels, and the growing role of evidence-backed value narratives as EU-level HTA advances.
I am quoted in the article as:
Jason Shafrin (FTI Consulting), author of our “Healthcare Economist’s Perspective” column, expects these dynamics to accelerate. In comments to The Evidence Base, they predict “G7 ghosting”, where manufacturers delay launches in high-income countries that sit in the MFN reference basket to reduce the risk of MFN-linked exemptions in the US. Whether or not it pans out, the prediction highlights a key tension coming into 2026: launch sequencing is increasingly being used as a pricing risk-management tool, not just a business timing decision.
Other topics of interest include:
You can read the full article Here.
